In the following video, Motley Fool health-care bureau chief Brenton Flynn takes a look at two different companies with drugs facing FDA approval decisions in February. He discusses ImmunoGen (NASDAQ: IMGN ) and its drug T-DM1, where approval is already expected by the market, as well as Dynavax (NASDAQ: DVAX ) and its hepatitis B vaccine Heplisav. Dynavax is the wildcard of this group, and Brenton gives his prediction for whether or not the drug will be approved.
A Massive New Market
While Dynavax awaits its fate in Hepatitis B, another company is hoping to strike it rich with a revolutionary new cure for the widespread Hepatitis C virus. The opportunity is huge, and its one AbbVie will need, becaus its cash cow, Humira, will eventually go to the patent slaughterhouse. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking; and, as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.